argenx company profile

ARGX · NASDAQ · USD

$960.04Change from previous close: −2.17%Absolute change: −$21.29

Close · November 13, 2026

Company profile

argenx has 1,863 employees and is headquartered in Amsterdam, Netherlands.

With revenue of $4.2 billion, argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases. It offers VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and VYVGART HYTRULO for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its development programs cover a range of other autoimmune conditions, and it has partnerships and license agreements with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie. The United States accounted for 83.2% of revenue, with the remainder coming from Japan, China and the rest of the world.

In the fiscal year ended December 2025, revenue rose 88.4% to $4.2 billion and net income reached $1.3 billion. The company had 1,863 employees. It was incorporated in 2008 and is headquartered in Amsterdam, the Netherlands. Its shares also trade on Euronext Brussels.

Company facts

Industry
Biotechnology
Headquarters
Laarderhoogtweg 25, 1101 EB, Amsterdam
Employees
1,863
Chief executive
Karen Massey
Founded
2008
Fiscal year
January - December
Listing
ARGX · NASDAQ
Currency
USD
ISIN
US04016X1019
Website
argenx.com

argenx and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
argenxARGXUnited States$60.37B1,86331.9%33.3
BeOne MedicinesONCUnited States$47.58B12,00017.8%53.4
ModernaMRNAUnited States$90.38B4,700-80.8%—
Royalty PharmaRPRXUnited States$39.85B10064.4%45.3
Revolution MedicinesRVMDUnited States$37.27B883-853.0%—
Regeneron PharmaceuticalsREGNUnited States$98.84B15,41030.4%21.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare argenx with its competitors